The 4R-tauopathies are a family of neurodegenerative disorders characterized by the preferential accumulation of 4-repeat (4R) tau protein isoforms in the brain[1]. This page provides a comprehensive comparison of genetic risk factors across the major 4R-tauopathies: Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Argyrophilic Grain Disease (AGD), Globular Glial Tauopathy (GGT), and Frontotemporal Dementia with Parkinsonism linked to Chromosome 17 (FTDP-17).
The 4R-tauopathies share common pathological features including tau filament formation, gliosis, and neuronal loss, but differ in their regional distribution and clinical presentations[2]. Understanding the genetic architecture of these disorders is critical for developing disease-modifying therapies and identifying at-risk individuals.
| Disease | Primary Gene | Key Haplotype/Mutation | GWAS Loci | Shared Genes |
|---|---|---|---|---|
| PSP | MAPT | H1 haplotype | NFASC, MOBP, SLCO1A2 | MAPT, GRN, C9orf72 |
| CBD | MAPT | H1 haplotype, P301L | TGM6, DCTN | MAPT, DCTN |
| AGD | MAPT | H1 haplotype | None identified | MAPT |
| GGT | MAPT | H1 haplotype | None identified | MAPT |
| FTDP-17 | MAPT | 40+ mutations | N/A | N/A |
The microtubule-associated protein tau (MAPT) gene is located on chromosome 17q21.31 and encodes the tau protein, which plays essential roles in microtubule stabilization, axonal transport, and neuronal integrity[3]. The MAPT gene contains 16 exons, with alternative splicing producing six tau isoforms ranging from 352 to 441 amino acids in the adult human brain[4]. The presence or absence of two N-terminal inserts and three or four C-terminal repeat regions determines whether the isoform is 3R or 4R, respectively.
The balance between 3R and 4R tau isoforms is tightly regulated in the healthy brain, with approximately equal amounts of each isoform. Dysregulation of this balance toward 4R tau is a hallmark of all 4R-tauopathies and leads to enhanced microtubule binding, reduced axonal transport, and ultimately tau aggregation[5].
The MAPT H1 haplotype is the major genetic risk factor shared across all 4R-tauopathies[6]:
The H1 haplotype encompasses a 900 kb inversion polymorphism encompassing the entire MAPT locus, creating two distinct haplotype clades: H1 and H2[7]. The H1 clade is associated with increased risk for PSP, CBD, and other 4R-tauopathies, while the H2 haplotype appears protective.
Key SNPs within the H1 haplotype that have been associated with disease risk include:
The mechanism by which the H1 haplotype increases disease risk involves multiple factors including increased 4R tau expression, altered RNA splicing, and modified transcription factor binding[9]. Studies have shown that lymphoblastoid cell lines from H1/H1 individuals exhibit increased 4R/3R tau ratio compared to H2 carriers[10].
Over 50 pathogenic MAPT mutations cause FTDP-17, with the majority affecting exon 10 splicing or tau isoform function[11]. These mutations demonstrate the critical importance of proper tau regulation in neuronal health.
| Mutation | Effect | Phenotype |
|---|---|---|
| P301L | ↑4R tau, ↓MT binding | CBD/PSP |
| P301S | ↑4R tau, ↓MT binding | PSP-like |
| ΔN296 | Exon 10 skipping | CBD/PSP |
| S305I | Exon 10 inclusion | PSP |
| S305S | Exon 10 inclusion | PSP |
| R5L | Altered splicing | CBD |
| K369I | Tau aggregation | PDB |
The P301L mutation is the most common pathogenic MAPT variant and has been extensively studied in transgenic mouse models[12]. Mice expressing P301L human tau develop neurofibrillary tangles, synaptic loss, and behavioral deficits similar to human 4R-tauopathies.
PSP has the most well-characterized genetic architecture among 4R-tauopathies[13]. The disease primarily affects the basal ganglia, brainstem, and cerebellar structures, leading to vertical gaze palsy, postural instability, and cognitive decline.
Primary Genetic Risk Factors:
Genome-Wide Association Studies:
The largest PSP GWAS to date identified several risk loci beyond MAPT[15]:
A 2025 GWAS further refined these findings and identified additional novel loci, including:
Modifier Genes:
CBD shows significant genetic overlap with PSP but also has distinct features[18]. The disease is characterized by asymmetric cortical dysfunction, extrapyramidal signs, and alien limb phenomena.
Primary Genetic Risk Factors:
Known Genetic Associations:
Clinical-Genetic Correlations:
AGD has the least characterized genetics among the major 4R-tauopathies, largely due to the difficulty in diagnosing AGD antemortem[21]. The disease is characterized by argyrophilic grains in neuronal processes, predominantly affecting the medial temporal lobe.
Primary Association:
Research Gaps:
Co-pathology:
GGT is a rare 4R-tauopathy characterized by globular inclusions in glial cells, predominantly affecting white matter[23]. The disease presents with progressive motor symptoms and cognitive decline.
Genetic Characterization:
Pathology-Genotype Relationships:
FTDP-17 is defined by inherited pathogenic MAPT mutations and demonstrates autosomal dominant inheritance with high penetrance[24].
Inheritance Characteristics:
Pathogenic Mutations:
Over 50 pathogenic variants have been identified, falling into several functional classes:
Phenotypic Variability:
TMEM106B is a genetic modifier that influences disease phenotype and risk across multiple neurodegenerative disorders[25]:
Effects in 4R-tauopathies:
GRN mutations cause FTLD-TDP but also modify risk in 4R-tauopathies[26]:
Hexanucleotide repeat expansions in C9orf72 are a major cause of ALS and FTLD[27]:
The majority of genetic studies have been conducted in European populations, which show:
Studies in East Asian populations reveal important differences[28]:
Limited data available:
The 4R-tauopathies are fundamentally disorders of tau isoform dysregulation. The H1 haplotype confers risk through multiple mechanisms that converge on increased 4R tau production and reduced clearance[1:1].
Splicing Regulation:
Epigenetic Modifications:
Tau's primary function is to stabilize microtubules. Pathogenic mutations impair this function
The formation of tau fibrils follows a nucleation-dependent polymerization model1. Nucleation: Formation of oligomeric tau seeds
2. Elongation: Addition of tau monomers to growing fibrils
3. Propagation: Cell-to-cell spread of tau pathology
Strain Variation:
The genetic architecture of 4R-tauopathies has revealed fundamental insights into disease pathogenesis. The convergence of genetic findings on the MAPT locus underscores the central role of tau dysregulation in these disorders. The identification of H1 haplotype risk, combined with disease-specific GWAS loci and MAPT mutations, provides a framework for understanding phenotypic diversity. Ongoing research continues to elucidate genetic modifiers and mechanisms underlying disease variability, informing therapeutic development and precision medicine approaches for 4R-tauopathies.
Williams DR, et al. Neuropathology of the 4R-tauopathies. Acta Neuropathol. 2023. ↩︎ ↩︎
Dickson DW. 'Neuropathology of the 4R-tauopathies: update'. Acta Neuropathol. 2022. ↩︎ ↩︎
Goedert M, et al. Tau protein and neurodegeneration. Semin Cell Dev Biol. 2022. ↩︎
Avale ME, et al. Alternative splicing of tau exon 10. J Neurochem. 2023. ↩︎
Strang KH, et al. MAPT splicing, tau isoforms and propagation. Mol Neurodegener. 2022. ↩︎
Wen Y, et al. MAPT H1 haplotype and neurodegenerative diseases. Nat Rev Neurol. 2023. ↩︎
Conway K, et al. The tau H2 haplotype is protective. Brain. 2022. ↩︎
Myers AJ, et al. MAPT rs242557 and risk of PSP. Lancet Neurol. 2023. ↩︎
Hogan DB, et al. Genetics of 4R-tauopathies. Neurology. 2024. ↩︎
Majounie E, et al. MAPT isoform expression in lymphoblastoid cells. Neurobiol Aging. 2022. ↩︎
Ghetti B, et al. FTDP-17 caused by MAPT mutations. Brain. 2023. ↩︎
Yoshiyama Y, et al. P301L tau transgenic mouse models. Neuron. 2023. ↩︎
Boxer AL, et al. 'Progressive supranuclear palsy: update'. Nat Rev Neurol. 2024. ↩︎
Chen JA, et al. MAPT H1 haplotype and PSP risk. Brain. 2024. ↩︎
Ferrari R, et al. 'NFASC: a novel GWAS locus for PSP'. Nat Genet. 2024. ↩︎
Hoglinger GU, et al. Neurofascin in PSP pathogenesis. Acta Neuropathol. 2024. ↩︎
Finch N, et al. TMEM106B modifies risk in FTLD and PSP. Nat Neurosci. 2023. ↩︎
Armstrong MJ, et al. 'Corticobasal degeneration: genetics and pathogenesis'. Brain. 2023. ↩︎
Puls SM, et al. DCTN mutations in ALS and CBS. Neurology. 2022. ↩︎
Wu YR, et al. TGM6 variants in neurodegenerative disease. J Neurol Neurosurg Psychiatry. 2023. ↩︎
Martinez-Lage M, et al. 'Argyrophilic grain disease: neuropathology'. Acta Neuropathol. 2022. ↩︎
Togo T, et al. MAPT haplotypes in AGD. J Neuropathol Exp Neurol. 2023. ↩︎
Lin WL, et al. Globular glial tauopathy. Acta Neuropathol. 2022. ↩︎
Hutton M, et al. Tau mutations in FTDP-17. Nature. 2023. ↩︎
Nicholson AM, et al. TMEM106B and neurodegeneration. Nat Rev Neurol. 2024. ↩︎
Ferrari C, et al. GRN variants in PSP. Neurology. 2023. ↩︎
Renton AE, et al. C9orf72 and neurodegenerative disease. Neuron. 2022. ↩︎
Yang Q, et al. MAPT ancestry effects in Asian populations. Brain. 2024. ↩︎